Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I)

BACKGROUND: Liver transplantation is the definitive treatment for many end-stage liver diseases. However, the life-long immunosuppression needed to prevent graft rejection causes clinically significant side effects. Cellular immunomodulatory therapies may allow the dose of immunosuppressive drugs to...

Descripción completa

Detalles Bibliográficos
Autores principales: Popp, Felix C, Fillenberg, Barbara, Eggenhofer, Elke, Renner, Philipp, Dillmann, Johannes, Benseler, Volker, Schnitzbauer, Andreas A, Hutchinson, James, Deans, Robert, Ladenheim, Deborah, Graveen, Cheryl A, Zeman, Florian, Koller, Michael, Hoogduijn, Martin J, Geissler, Edward K, Schlitt, Hans J, Dahlke, Marc H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166276/
https://www.ncbi.nlm.nih.gov/pubmed/21798013
http://dx.doi.org/10.1186/1479-5876-9-124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166276/
https://www.ncbi.nlm.nih.gov/pubmed/21798013
http://dx.doi.org/10.1186/1479-5876-9-124

Ejemplares similares